Entering text into the input field will update the search result below

RBC maintains Outperform on Ariad

Sep. 06, 2013 10:56 PM ETARIAD Pharmaceuticals, Inc. (ARIA) StockARIABy: Colin Lokey, SA News Editor1 Comment
  • RBC's Michael Yee maintains an Outperform rating on Ariad Pharmaceuticals (NASDAQ:ARIA).
  • Yee is looking forward to Iclusig data to be presented at a meeting of the American Society of Hematology this December.
  • Price target is $28, representing a 25% upside from Friday's close.
  • See also: Iclusig TRx +5.4% w/w

Recommended For You

Related Stocks

SymbolLast Price% Chg
ARIA--
ARIAD Pharmaceuticals, Inc.